Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

2.00
Hdl Handle:
http://hdl.handle.net/10541/55801
Title:
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.
Authors:
Ryan, G; Martinelli, Giovanni; Kuper-Hommel, M; Tsang, R; Pruneri, G; Yuen, K; Roos, D; Lennard, A; Devizzi, L; Crabb, S; Hossfeld, D; Pratt, Guy; Dell'Olio, M; Choo, S P; Bociek, R G; Radford, John A ( 0000-0001-7898-2786 ) ; Lade, S; Gianni, A M; Zucca, E; Cavalli, Franco; Seymour, J F
Abstract:
BACKGROUND: Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features, prognostic factors, patterns of failure, and treatment outcomes. PATIENTS AND METHODS: A retrospective international study of 204 eligible patients presenting to the International Extranodal Lymphoma Study Group-affiliated institutions from 1980 to 2003. RESULTS: Median age was 64 years, with 95% of patients presenting with unilateral disease. Median overall survival (OS) was 8.0 years, and median progression-free survival 5.5 years. In multifactor analysis, favourable International Prognostic Index score, anthracycline-containing chemotherapy, and radiotherapy (RT) were significantly associated with longer OS (each P < or = 0.03). There was no benefit from mastectomy, as opposed to biopsy or lumpectomy only. At a median follow-up time of 5.5 years, 37% of patients had progressed--16% in the same or contralateral breast, 5% in the central nervous system, and 14% in other extranodal sites. CONCLUSIONS: The combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT produced the best outcome in the pre-rituximab era. A prospective trial on the basis of these results should be pursued to confirm these observations and to determine whether the impact of rituximab on the patterns of relapse and outcome parallels that of DLBCL presenting at other sites.
Affiliation:
Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. gail.ryan@petermac.org
Citation:
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. 2008, 19 (2):233-41 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
Feb-2008
URI:
http://hdl.handle.net/10541/55801
DOI:
10.1093/annonc/mdm471
PubMed ID:
17932394
Type:
Article
Language:
en
ISSN:
1569-8041
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorRyan, G-
dc.contributor.authorMartinelli, Giovanni-
dc.contributor.authorKuper-Hommel, M-
dc.contributor.authorTsang, R-
dc.contributor.authorPruneri, G-
dc.contributor.authorYuen, K-
dc.contributor.authorRoos, D-
dc.contributor.authorLennard, A-
dc.contributor.authorDevizzi, L-
dc.contributor.authorCrabb, S-
dc.contributor.authorHossfeld, D-
dc.contributor.authorPratt, Guy-
dc.contributor.authorDell'Olio, M-
dc.contributor.authorChoo, S P-
dc.contributor.authorBociek, R G-
dc.contributor.authorRadford, John A-
dc.contributor.authorLade, S-
dc.contributor.authorGianni, A M-
dc.contributor.authorZucca, E-
dc.contributor.authorCavalli, Franco-
dc.contributor.authorSeymour, J F-
dc.date.accessioned2009-03-16T17:16:16Z-
dc.date.available2009-03-16T17:16:16Z-
dc.date.issued2008-02-
dc.identifier.citationPrimary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. 2008, 19 (2):233-41 Ann. Oncol.en
dc.identifier.issn1569-8041-
dc.identifier.pmid17932394-
dc.identifier.doi10.1093/annonc/mdm471-
dc.identifier.urihttp://hdl.handle.net/10541/55801-
dc.description.abstractBACKGROUND: Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features, prognostic factors, patterns of failure, and treatment outcomes. PATIENTS AND METHODS: A retrospective international study of 204 eligible patients presenting to the International Extranodal Lymphoma Study Group-affiliated institutions from 1980 to 2003. RESULTS: Median age was 64 years, with 95% of patients presenting with unilateral disease. Median overall survival (OS) was 8.0 years, and median progression-free survival 5.5 years. In multifactor analysis, favourable International Prognostic Index score, anthracycline-containing chemotherapy, and radiotherapy (RT) were significantly associated with longer OS (each P < or = 0.03). There was no benefit from mastectomy, as opposed to biopsy or lumpectomy only. At a median follow-up time of 5.5 years, 37% of patients had progressed--16% in the same or contralateral breast, 5% in the central nervous system, and 14% in other extranodal sites. CONCLUSIONS: The combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT produced the best outcome in the pre-rituximab era. A prospective trial on the basis of these results should be pursued to confirm these observations and to determine whether the impact of rituximab on the patterns of relapse and outcome parallels that of DLBCL presenting at other sites.en
dc.language.isoenen
dc.subjectAnthracyclin-Based Chemotherapyen
dc.subjectBreasten
dc.subjectLarge B-Cell Lymphomaen
dc.subjectRadiotherapyen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshInternational Cooperation-
dc.subject.meshLymphoma, Large B-Cell, Diffuse-
dc.subject.meshMiddle Aged-
dc.subject.meshMulticenter Studies as Topic-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNeoplasm Staging-
dc.subject.meshProbability-
dc.subject.meshPrognosis-
dc.subject.meshRetrospective Studies-
dc.subject.meshRisk Assessment-
dc.subject.meshSocieties, Medical-
dc.subject.meshSurvival Analysis-
dc.titlePrimary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.en
dc.typeArticleen
dc.contributor.departmentPeter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. gail.ryan@petermac.orgen
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.